RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
RegeneRx Biopharmaceuticals Stock

RegeneRx Biopharmaceuticals Net Income 2024

RegeneRx Biopharmaceuticals Net Income

-1.73 M USD

Ticker

RGRX

ISIN

US75886X1081

WKN

875295

In 2024, RegeneRx Biopharmaceuticals's profit amounted to -1.73 M USD, a 8.12% increase from the -1.6 M USD profit recorded in the previous year.

The RegeneRx Biopharmaceuticals Net Income history

YEARNET INCOME (undefined USD)
2022-1,727.46
2021-1,597.76
2020-1,523.37
2019-1,486.81
2018-1,993.55
2017286.49
2016229.13
2015-5,270.48
2014-2,753.64

RegeneRx Biopharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into RegeneRx Biopharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by RegeneRx Biopharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects RegeneRx Biopharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of RegeneRx Biopharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into RegeneRx Biopharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing RegeneRx Biopharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on RegeneRx Biopharmaceuticals’s growth potential.

RegeneRx Biopharmaceuticals Revenue, EBIT and net profit per share

DateRegeneRx Biopharmaceuticals RevenueRegeneRx Biopharmaceuticals EBITRegeneRx Biopharmaceuticals Net Income
202276,760 undefined-1.4 M undefined-1.73 M undefined
202176,760 undefined-1.33 M undefined-1.6 M undefined
202076,760 undefined-1.29 M undefined-1.52 M undefined
201976,760 undefined-1.26 M undefined-1.49 M undefined
201869,670 undefined-1.32 M undefined-1.99 M undefined
201756,650 undefined-1.44 M undefined286,490 undefined
201693,310 undefined-1.67 M undefined229,130 undefined
201560,610 undefined-1.71 M undefined-5.27 M undefined
20140 undefined-1.56 M undefined-2.75 M undefined

RegeneRx Biopharmaceuticals stock margins

The RegeneRx Biopharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of RegeneRx Biopharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for RegeneRx Biopharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the RegeneRx Biopharmaceuticals's sales revenue. A higher gross margin percentage indicates that the RegeneRx Biopharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the RegeneRx Biopharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the RegeneRx Biopharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the RegeneRx Biopharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the RegeneRx Biopharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the RegeneRx Biopharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

RegeneRx Biopharmaceuticals Margin History

RegeneRx Biopharmaceuticals Gross marginRegeneRx Biopharmaceuticals Profit marginRegeneRx Biopharmaceuticals EBIT marginRegeneRx Biopharmaceuticals Profit margin
2022100.31 %-1,826.46 %-2,250.47 %
202191.19 %-1,730.73 %-2,081.5 %
2020100.31 %-1,686.48 %-1,984.59 %
2019100.31 %-1,643.93 %-1,936.96 %
2018100.31 %-1,899.48 %-2,861.42 %
2017100.31 %-2,550.1 %505.72 %
2016100.31 %-1,794.04 %245.56 %
2015100.31 %-2,820.56 %-8,695.73 %
2014100.31 %0 %0 %

RegeneRx Biopharmaceuticals Aktienanalyse

What does RegeneRx Biopharmaceuticals do?

RegeneRx Biopharmaceuticals Inc is a biotechnology company focused on the development and commercialization of drugs for the treatment of diseases. The company is headquartered in Rockville, Maryland and was founded in 1982. Since its inception, RegeneRx has brought various products to market and is known for its research in tissue regeneration. The company started its early years with research in the field of nerve regeneration. As a result of this research, RegeneRx developed its first chemical called Thymosin beta 4 (Tβ4). Tβ4 is a naturally occurring protein produced in the human body. It serves as a growth factor for cells and plays an important role in healing damaged tissue. RegeneRx used this knowledge and began intensive work on the growth of Tβ4 in the laboratory. The company's researchers soon realized that Tβ4 was not only important for nerve regeneration, but could also be used in skin damage, stroke, and heart attack treatment. The researchers continued to work on the substance and in 1999 successfully brought the so-called Eye Drop product A3G12 to the market. This product is used to treat eye injuries and infections. In the following years, RegeneRx continued to research Tβ4. It was found that Tβ4 could also be successfully used in COPD (Chronic Lung Problems), wound healing, and bone disorders. Various products were developed for this purpose, available under the names RGN-137, RGN-259, and RGN-352. RegeneRx has also formed partnerships with other pharmaceutical companies such as Axio Biosolutions and Gtree BNP, and has successfully collaborated with them. In early 2021, it was decided that RegeneRx would expand its expertise in the Asian market and signed an agreement with Gtree BNP. The two companies planned to market RegeneRx products RGN-503 and RGN-352 in South Korea. Overall, RegeneRx Biopharmaceuticals Inc. has developed an impressive list of products that have successfully undergone patent and regulatory processes. These products treat a variety of diseases and injuries. RegeneRx is committed to continuing its research in this field and developing new products to help improve the health and well-being of patients worldwide. The company's business model primarily focuses on research and development. It has expanded in recent years due to the high potential of Tβ4 and its use in many medical areas. RegeneRx expects that by expanding the use of Tβ4, there will be greater acceptance and demand for its products worldwide. RegeneRx Biopharmaceuticals Inc is a company operating in the field of regenerative medicine. The products are typically positioned in the higher price range, in line with the company's market positioning. The company has successfully collaborated with other pharmaceutical companies in the past and is expected to form further alliances. RegeneRx sees itself as a leading biotechnology company focused on innovative drugs. RegeneRx Biopharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding RegeneRx Biopharmaceuticals's Profit Margins

The profit margins of RegeneRx Biopharmaceuticals represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of RegeneRx Biopharmaceuticals's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating RegeneRx Biopharmaceuticals's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

RegeneRx Biopharmaceuticals's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When RegeneRx Biopharmaceuticals’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about RegeneRx Biopharmaceuticals stock

How much profit has RegeneRx Biopharmaceuticals made this year?

RegeneRx Biopharmaceuticals has made -1.73 M USD this year.

How has the profit developed compared to last year?

The profit has increased by 8.12% compared to last year increased

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does RegeneRx Biopharmaceuticals publish its earnings?

RegeneRx Biopharmaceuticals publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of RegeneRx Biopharmaceuticals?

The profits of RegeneRx Biopharmaceuticals are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of RegeneRx Biopharmaceuticals?

You can learn more about the earnings of RegeneRx Biopharmaceuticals by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does RegeneRx Biopharmaceuticals pay?

Over the past 12 months, RegeneRx Biopharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, RegeneRx Biopharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of RegeneRx Biopharmaceuticals?

The current dividend yield of RegeneRx Biopharmaceuticals is .

When does RegeneRx Biopharmaceuticals pay dividends?

RegeneRx Biopharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of RegeneRx Biopharmaceuticals?

RegeneRx Biopharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of RegeneRx Biopharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is RegeneRx Biopharmaceuticals located?

RegeneRx Biopharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von RegeneRx Biopharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of RegeneRx Biopharmaceuticals from 10/7/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/7/2024.

When did RegeneRx Biopharmaceuticals pay the last dividend?

The last dividend was paid out on 10/7/2024.

What was the dividend of RegeneRx Biopharmaceuticals in the year 2023?

In the year 2023, RegeneRx Biopharmaceuticals distributed 0 USD as dividends.

In which currency does RegeneRx Biopharmaceuticals pay out the dividend?

The dividends of RegeneRx Biopharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von RegeneRx Biopharmaceuticals

Our stock analysis for RegeneRx Biopharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of RegeneRx Biopharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.